Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HK1 | P19367 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GALK1 | P51570 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44824 | 0.79 | HTR5A (0.53) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL5629 | 0.78 | — | — | |
| Indoline SCHEMBL29360339 | 0.78 | — | — | |
| Indoline SCHEMBL28048786 | 0.77 | HTR2C (0.46) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL23295083 | 0.76 | HTR2C (0.50) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL11401846 | 0.76 | HTR2C (0.50) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL8194348 | 0.76 | HTR2C (0.50) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL1587228 | 0.76 | HTR2C (0.50) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL4903255 | 0.76 | HTR2C (0.50) | MAPTNPC1KDM4EMEN1KMT2A | |
| Indoline SCHEMBL10723456 | 0.76 | HTR2C (0.50) | MAPTNPC1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| US-7323458-B1 | Dihydrobenzodiazepins and their use for treating dyslipidemia | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7323458-B1 | Dihydrobenzodiazepins and their use for treating dyslipidemia | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-01-29 | — | — | US | disclosed |
| EP-1189890-B1 | DIHYDROBENZODIAZEPINS AND THEIR USE FOR TREATING DYSLIPIDEMIA | MERCK PATENT GMBH (DE) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | MAPT 4710/4885NPC1 2463/4885KDM4E 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.